Adenoviral Vector E3 Partial Deletion for Stable Toxic Transgene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing adenoviral vectors used in vaccine development and gene therapy become unstable when expressing toxic transgene products due to the E3 domain, leading to replication competence and instability.
Innovation Solution
Adenoviral vectors are modified by selective deletion of E3 ORFs (ORF3, ORF4, ORF5, ORF6, and ORF7) and inclusion of anti-apoptotic proteins, either native or from other sources, to maintain stability and replication incompetence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the E3 domain is retained in adenoviral vectors, then the vectors maintain replication competence and anti-apoptotic function, but the vectors become unstable when expressing toxic transgene products
Solution Approach 1:
The patent extracts and removes the E3 domain from the adenoviral vector genome. This deletion eliminates the anti-apoptotic function that causes instability when expressing toxic transgenes, while the vector retains sufficient replication competence through other mechanisms to achieve therapeutic efficacy.
Solution Approach 2:
The patent changes the genomic composition parameter of the adenoviral vector by deleting specific E3 region open reading frames (ORFs). This parameter change modifies the vector's biological properties to reduce instability associated with toxic transgene expression while maintaining essential viral functions.
2Reliability
If the E3 domain is deleted in adenoviral vectors, then the vectors maintain stability when expressing toxic transgene products, but the vectors lose replication competence and anti-apoptotic function
Solution Approach 1:
The patent applies partial deletion of the E3 domain by removing only specific ORFs (such as E3-19K, E3-4.2K, E3-14.7K) while potentially retaining other E3 region sequences. This partial action maintains stability benefits while preserving sufficient replication competence for therapeutic effectiveness.
3Productivity
If adenoviral vectors express toxic transgene products, then the therapeutic effect is enhanced, but the vectors become unstable and lose replication control
Solution Approach 1:
The patent removes the E3 domain that mediates the instability caused by toxic transgene expression. This extraction eliminates the harmful interaction between E3 anti-apoptotic proteins and toxic transgenes, allowing high-level transgene expression without compromising vector genomic stability.
Solution Approach 2:
The patent converts the harmful effect of E3 domain presence (instability with toxic transgenes) into a benefit by deleting E3. The deletion, which initially seems to reduce viral fitness, actually enables stable expression of toxic transgenes that would otherwise cause vector collapse, thereby enhancing therapeutic productivity.
Data Source
AI summary
This disclosure provides replication-incompetent adenoviral vectors useful in vaccine development and gene therapy. The disclosed vectors comprise a selective deletion of E3 and are particularly useful for preparation of vaccines development and for gene therapy using toxic transgene products that result in vector instability that occurs when the entire E3 domain is deleted.